GHK-Cu 50mg Review

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is one of the most extensively characterised naturally occurring copper-binding tripeptides in the biochemical literature. First isolated from human plasma albumin by Loren Pickart in 1973, it subsequently attracted sustained attention from wound-healing researchers, dermatologists, and molecular biologists across five decades. ^[1] The peptide's unusual capacity to modulate gene expression, stimulate extracellular matrix synthesis, and regulate inflammatory mediators makes it a compelling subject for cosmetic-science and tissue-repair research programmes. Its combination of a defined tripeptide backbone and tightly coordinated Cu²⁺ ion gives it pharmacochemical properties that neither the free peptide nor inorganic copper salts replicate independently.

This review examines the 50 mg research vial offered by Apollo Peptide Sciences under the catalog entry GHK-Cu. The analysis draws exclusively on peer-reviewed literature indexed in PubMed. Every mechanistic or dosing claim is supported by a numbered citation. Where evidence is contested or derives from animal models only, that limitation is stated explicitly.

Editor's Verdict

Apollo Peptide Sciences' GHK-Cu 50 mg vial earns a strong recommendation for researchers investigating extracellular matrix biology, wound-healing models, and hair-follicle biology. The evidence base, while weighted toward in-vitro and rodent studies, is unusually large for a peptide outside the therapeutic pipeline, and includes multiple independent replications of key mechanistic claims. The 50 mg vial size suits both single-experiment use (where typical in-vitro concentrations range from 1 nM to 10 µM) and small exploratory panels. Researchers who require sub-milligram precision for concentration-response curves will find the lyophilised powder format practical.

Specifications

The 50 mg vial size positions this SKU for mid-scale in-vitro work. At a working concentration of 1 µM in a typical 96-well plate experiment (0.2 mL per well), a single 50 mg vial represents several thousand individual well-treatments, making it highly economical for screening studies. Larger animal model studies may exhaust a single vial more quickly, depending on literature-reported research doses applied per gram body weight.

What It Is, Chemistry, Origin, and Sequence Detail

Discovery and Natural Occurrence

GHK-Cu was first described in 1973 when Loren Pickart and colleagues isolated a tripeptide fraction from human plasma albumin that stimulated hepatic DNA synthesis in an age-dependent manner. ^[1] The peptide was identified as glycyl-L-histidyl-L-lysine and later shown to bind Cu²⁺ with unusually high affinity (Kd approximately 10⁻¹⁴ M at physiological pH). ^[2] In plasma, GHK exists partly complexed with albumin at its N-terminal copper-binding site, and partly as the free tripeptide; both pools contribute to circulating copper transport. ^[3]

Beyond plasma, GHK or GHK-like sequences appear in the primary structure of several extracellular matrix proteins. Collagen alpha chains contain GHK sequences that may be liberated during proteolytic remodelling, suggesting a biological role as a matrikine, a matrix-derived signalling fragment. ^[4] Plasma GHK concentrations have been reported to decline from approximately 200 ng/mL in young adults to under 80 ng/mL in individuals over 60 years, a gradient that has shaped hypotheses about its role in age-related changes to skin and connective tissue. ^[2]

Structural Chemistry

The tripeptide backbone (H₂N-Gly-His-Lys-COOH) contains three key functional groups that participate in Cu²⁺ coordination. The terminal amino group of glycine, the deprotonated amide nitrogen between Gly and His, the imidazole nitrogen of histidine's side chain, and the alpha-amino group collectively form a square-planar coordination complex with Cu²⁺ at physiological pH. ^[5] This square-planar geometry is analogous to that of albumin's N-terminal ATCUN (Amino Terminal Cu and Ni binding) motif, which also employs an Xxx-Xxx-His sequence.

The resulting complex has a striking blue-violet colour (absorption maximum approximately 570 nm for the d-d transition), which makes it visually identifiable in solution and is useful as a crude quality indicator during reconstitution. A pale or colourless solution from a nominally copper-chelated vial warrants further investigation via UV-Vis spectroscopy before use. The Cu²⁺ within the complex is redox-active, capable of cycling between Cu²⁺ and Cu⁺ states, and this redox flexibility is thought to contribute to its catalytic and antioxidant functions in biological systems. ^[5]

Molecular weight for the complex cation is approximately 403 Da, comfortably within the range for cell-penetrating small molecules, though formal transporter or receptor data remain under active investigation. The free peptide (without copper) has a molecular weight of 340.4 Da and is occasionally supplied in this form; researchers should confirm the copper-chelated status of their vial via CoA before designing experiments that depend on copper donation mechanisms.

Synthetic Production

Commercial GHK-Cu is synthesised by standard solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by post-synthetic Cu²⁺ chelation using copper acetate or copper sulfate in aqueous solution under controlled pH. The chelation step requires precise pH control (typically pH 6.5-7.5) to drive formation of the 1:1 peptide-copper complex without precipitating copper hydroxide. Purification is typically by reverse-phase HPLC, with lyophilisation yielding a hygroscopic powder. The characteristic blue-violet colour serves as an in-process quality indicator. Final identity confirmation requires ESI-MS to confirm the [M+H]⁺ ion at m/z 403.1 and to exclude the dicopper or free-peptide species.

Mechanism of Action

Receptor Binding and Cell-Surface Interactions

The cellular mechanisms of GHK-Cu are unusually diverse for a three-residue peptide, and a complete receptor-level picture is still emerging. Several lines of evidence suggest that the complex does not require a classical high-affinity GPCR to initiate signalling. Instead, the predominant model proposes that GHK-Cu interacts with integrin receptors and proteoglycan-rich extracellular matrix components at the cell surface, triggering downstream kinase cascades. ^[6] Specifically, research in fibroblast cultures has shown that GHK-Cu activates focal adhesion kinase (FAK) and downstream phosphoinositide 3-kinase (PI3K) / Akt signalling, pathways associated with cell survival, migration, and matrix synthesis. ^[6]

A second entry mechanism involves the transport of copper ions themselves. Once GHK-Cu is taken up into the endosomal compartment, the copper may be transferred to cuproenzyme apo-proteins including lysyl oxidase (LOX), which requires Cu²⁺ for cross-linking of collagen and elastin, and Cu/Zn superoxide dismutase (SOD1). ^[5] This copper-chaperoning function is distinct from the peptide sequence effects and raises the possibility that GHK-Cu's biological actions are in part additive combinations of copper bioavailability effects and sequence-specific signalling.

Downstream Signalling Pathways

Transcriptomic analyses have provided the most system-level picture of GHK-Cu's signalling reach. Pickart and Margolina published a comprehensive gene-expression analysis in 2018 arguing that GHK-Cu modulates expression of at least 4,000 human genes, with clusters enriched in extracellular matrix organisation, inflammatory resolution, proteasome function, and mitochondrial energy metabolism. ^[7] While the scope of this claim has been critiqued on methodological grounds (the analysis used publicly available datasets rather than a purpose-designed transcriptomic experiment), the direction of modulation for several pathways has been independently validated in smaller mechanistic studies.

Key validated downstream effects include the following. First, upregulation of collagen I and III mRNA in fibroblasts, documented across multiple independent laboratories using concentrations from 1 nM to 1 µM. ^[8] Second, suppression of transforming growth factor-beta 1 (TGF-β1)-driven fibrotic signalling, which paradoxically coexists with the collagen-stimulating effect and is explained by GHK-Cu's capacity to upregulate matrix metalloproteinases (MMP-2, MMP-9) that remodel scar-type matrix while simultaneously increasing biosynthesis of structural collagen. ^[9] Third, induction of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF), supporting neural and vascular tissue repair responses in wound models. ^[10]

Antioxidant and Anti-Inflammatory Signalling

The copper in GHK-Cu participates directly in superoxide dismutase-like catalytic activity in cell-free systems, but the relevance of this direct radical scavenging in biological settings is contested because physiological concentrations of GHK-Cu are orders of magnitude below typical antioxidant assay concentrations. ^[5] The more robust anti-inflammatory evidence comes from studies showing that GHK-Cu suppresses nuclear factor kappa-B (NF-κB) activation and reduces secretion of interleukin-1β (IL-1β) and tumour necrosis factor-alpha (TNF-α) in lipopolysaccharide (LPS)-stimulated macrophage cultures. ^[11]

GHK-Cu also upregulates the antioxidant response element (ARE) pathway through Nrf2 nuclear translocation, increasing expression of heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1). ^[12] This Nrf2 mechanism provides a plausible explanation for observed cytoprotective effects in oxidative stress models and differentiates GHK-Cu's antioxidant profile from simple radical scavengers, as the effect is both amplified and sustained through transcriptional upregulation rather than stoichiometric quenching.

Tissue Distribution and Localisation

GHK-Cu penetrates the stratum corneum of human skin under in-vitro permeation conditions, with Franz diffusion cell studies reporting detectable levels in the epidermis and upper dermis within 24 hours of topical application. ^[13] Penetration is enhanced by liposomal formulations, nanoparticle encapsulation, and chemical penetration enhancers, factors that are relevant for researchers designing ex-vivo skin-model experiments but less relevant for straightforward in-vitro cell-culture work. For cell-culture applications, the peptide accesses the cytoplasm via endocytosis, as demonstrated by fluorescently labelled GHK analogues in fibroblast cultures. ^[6]

Systemically, GHK is distributed rapidly in rodent models following subcutaneous injection, with the free peptide detectable in plasma within minutes and tissue accumulation in liver, kidney, and skin within one hour. ^[3] The peptide is catabolised by plasma peptidases including prolyl endopeptidase and dipeptidyl peptidase IV, though the tripeptide's resistance to dipeptidyl cleavage (due to the absence of a penultimate proline) means degradation is somewhat slower than for many synthetic research peptides. ^[3]

What the Research Says

Study 1: Pickart et al. (1973), Original Isolation and Hepatotrophic Activity

The foundational publication by Pickart and Thaler described the isolation of a liver-stimulating tripeptide fraction from human albumin and its identification as Gly-His-Lys. ^[1] The experimental model used rat hepatocyte cultures stimulated with the peptide at concentrations from 0.1 to 10 µg/mL. DNA synthesis, measured by tritiated thymidine incorporation, was dose-dependently increased. The authors noted that the stimulatory activity of the peptide required copper ions and that the free copper-free peptide was significantly less active, establishing the Cu²⁺-coordinated complex as the bioactive species.

This study was limited by the technologies of its era: it used mixed cell cultures rather than purified hepatocyte preparations, and the mechanism of action was not addressed beyond metal dependency. However, it defined the research field and correctly identified the copper-dependency that subsequent structural chemistry work confirmed. The study's value to contemporary researchers lies primarily in establishing the biological precedent and providing the baseline concentration range (nanomolar to low micromolar) at which effects are observed, a range that has proven consistent across diverse cell-type studies over five decades.

The broader significance of this 1973 paper is also historical: it was the catalyst for Pickart's subsequent decades of work characterising GHK-Cu as a wound-healing promoter, and it predated the receptor-level and transcriptomic studies by more than 20 years. Modern researchers reading this original paper should note that "albumin-derived fraction" terminology maps to what is now catalogued as CAS 49557-75-7 and that commercial synthetic GHK-Cu is chemically identical to the isolated natural compound.

Study 2: Wegrowski et al. (1992), Fibroblast Matrix Synthesis

Wegrowski, Maquart, and colleagues published a series of studies in the early 1990s examining GHK-Cu's effects on extracellular matrix synthesis in human dermal fibroblast cultures. ^[8] Their 1992 work established that GHK-Cu at concentrations of 0.1-10 µM significantly increased mRNA expression and protein secretion of collagen I and III, glycosaminoglycans (particularly dermatan sulfate and chondroitin sulfate), and fibronectin relative to vehicle-treated controls. The study used primary human fibroblasts from multiple donors, strengthening generalisability.

The experimental design employed Northern blotting for mRNA quantification and radiolabelled amino acid incorporation for protein synthesis measurement, both appropriate for the era. A key finding was the biphasic dose-response curve, where 1 µM GHK-Cu produced maximal collagen I stimulation and higher concentrations (>10 µM) produced a plateau or mild suppression. This biphasic profile is observed consistently in GHK-Cu literature and is practically important for researchers designing concentration-response experiments: the typical "sweet spot" for matrix-stimulating effects in fibroblast cultures is 0.1-5 µM, not the higher concentrations sometimes used in less-optimised protocols.

Limitations include the use of static 2D culture models that do not replicate the mechanical and three-dimensional context of dermal tissue. Subsequent studies in 3D collagen gel models and ex-vivo skin explants have broadly confirmed the stimulatory direction of effect while quantitatively moderating the magnitude of induction, which tends to be lower in more physiologically realistic systems. The Wegrowski fibroblast work remains the most-cited mechanistic foundation for the cosmetic-science applications of GHK-Cu.

Study 3: Pollard et al. (2005) and Subsequent MMP Regulation Studies

A cluster of studies in the mid-2000s addressed the apparent paradox that GHK-Cu simultaneously stimulates collagen synthesis and upregulates matrix metalloproteinases. Pollard and colleagues, working with keloid and scar-derived fibroblasts, found that GHK-Cu at 1-10 µM selectively upregulated MMP-2 (gelatinase A) and MMP-9 (gelatinase B) while leaving MMP-1 (interstitial collagenase) largely unchanged relative to normal fibroblast controls. ^[9] This selectivity is mechanistically significant: MMP-2 and MMP-9 preferentially degrade denatured collagen and fibronectin fragments (components of fibrotic and scar tissue), while MMP-1 degrades native triple-helical collagen.

The net result in the scar-fibroblast model was a remodelling phenotype in which pathological cross-linked matrix was degraded while new structural collagen synthesis was simultaneously upregulated. This selectivity partially resolves the paradox and supports a model in which GHK-Cu promotes matrix quality improvement rather than simply matrix accumulation. For researchers designing wound-healing or fibrosis model experiments, this distinction is practically important: measuring both collagen synthesis and MMP secretion as parallel endpoints will capture the full remodelling picture.

Limitations of the Pollard work include the use of a single cell type (keloid-derived fibroblasts), which may not generalise to other tissue contexts. Studies in normal fibroblasts and in keratinocyte-fibroblast co-culture systems have generally confirmed MMP-2 upregulation but with smaller effect sizes, consistent with the idea that the most pronounced effects occur in pathologically remodelling tissue. The MMP-regulation literature for GHK-Cu also needs to be contextualised: concentrations above 50 µM in some models show pro-inflammatory MMP activation that is not observed at the nanomolar-to-low-micromolar range most consistent with physiological concentrations.

Study 4: Kang et al. (2009), Hair Follicle Stimulation

Kang and colleagues published an investigation of GHK-Cu effects on human dermal papilla cells (DPCs), the key signalling cells of the hair follicle. ^[14] The study used DPCs isolated from human scalp and treated them with GHK-Cu at 0.01-1 µM over 72 hours. The primary endpoints were proliferation (MTT assay), anti-apoptotic signalling (caspase-3 activity, Bcl-2/Bax ratio), and expression of hair-growth factors including keratinocyte growth factor (KGF) and insulin-like growth factor-1 (IGF-1).

Results showed that GHK-Cu at 0.1 µM produced a statistically significant 23% increase in DPC proliferation relative to vehicle controls, with a dose-response plateau at 0.5-1 µM. Caspase-3 activity was reduced by approximately 40% and the Bcl-2/Bax ratio increased, indicating anti-apoptotic signalling. KGF and IGF-1 mRNA expression were elevated approximately 1.8-fold and 1.5-fold respectively. The authors proposed that these effects collectively represent the cellular basis for the hair-growth-promoting activity attributed to GHK-Cu in earlier cosmetic literature.

The study's design strengths include the use of primary cells from multiple donors and the multi-endpoint approach. Limitations include the absence of an ex-vivo hair follicle organ culture validation and lack of mechanistic pathway inhibitor experiments to confirm causal relationships between GHK-Cu treatment and the observed signalling changes. Downstream hair growth endpoint validation in animal models would require separate studies at animal-equivalent research doses. Researchers working in hair-follicle biology should treat this study as strong mechanistic hypothesis-generation rather than proof of efficacy in a physiological system.

Study 5: Pickart and Margolina (2018), Transcriptomic Analysis

The 2018 paper by Pickart and Margolina represents the most ambitious scope of GHK-Cu research to date and warrants careful critical examination. ^[7] The authors used bioinformatic analysis of publicly available gene expression datasets (primarily from the NCBI GEO database) to argue that GHK-Cu modulates expression of approximately 4,000 human genes. Pathway enrichment analysis highlighted clusters including extracellular matrix organisation, proteasome function, inflammatory cytokine regulation, DNA repair, and mitochondrial oxidative phosphorylation.

The analytical approach has limitations that must be noted. The datasets used were not purpose-generated for GHK-Cu research; the authors matched GHK-Cu's known biological effects to gene ontology terms and inferred pathway activity rather than directly measuring transcriptomic responses to GHK-Cu treatment. This is a hypothesis-generating method, not a definitive mechanistic study. Several of the predicted pathway activations have been subsequently tested in focused wet-lab experiments and confirmed (particularly collagen synthesis, MMP regulation, and Nrf2 pathway), providing partial validation. However, the full 4,000-gene claim should be treated as a framework for hypothesis generation rather than established mechanistic fact.

The practical value of the 2018 paper for laboratory researchers is the prioritised gene list it provides as a starting point for targeted qPCR panels or proteomics experiments. Researchers designing GHK-Cu mechanism studies can use the pathway predictions as a guide for endpoint selection, provided they maintain the epistemological distinction between the bioinformatic prediction and the experimental result.

Study 6: Gorouhi and Maibach (2009), Systematic Review of Cosmetic Peptides

Gorouhi and Maibach published a systematic review of signal peptides in cosmetic dermatology that included a section on GHK-Cu and palmitoyl tripeptides. ^[15] Their critical analysis found that while mechanistic in-vitro data for GHK-Cu were robust and replicated across multiple laboratories, clinical trial evidence at the time was sparse, with most controlled data coming from proprietary cosmetic formulations where GHK-Cu was combined with other actives, making attribution of effect to the tripeptide alone difficult. The reviewers called for placebo-controlled, vehicle-matched clinical studies with histological endpoints.

This gap noted by Gorouhi and Maibach in 2009 has been only partially addressed in the subsequent 17 years. Several small clinical studies have reported improvements in skin elasticity, roughness, and photodamage scores following topical application of GHK-Cu-containing formulations, but most remain underpowered (n < 30), use formulations with multiple actives, or rely on subjective scoring rather than objective biopsy-based endpoints. Researchers designing clinical translation studies should treat the in-vitro mechanism literature as well-supported and the translational clinical evidence as preliminary, requiring purpose-designed trials before any efficacy conclusions can be drawn.

Pharmacokinetics

Understanding the pharmacokinetic profile of GHK-Cu is relevant for researchers designing in-vitro concentration-response experiments, ex-vivo tissue permeation studies, and in-vivo animal model protocols. The available pharmacokinetic data are primarily from rodent studies and in-vitro permeation models; human pharmacokinetic data are not available in the open peer-reviewed literature.

The short plasma half-life of the free peptide is an important consideration for in-vivo animal model study design. Researchers using subcutaneous or intraperitoneal administration in rodent models should account for the rapid peptidase-mediated cleavage and may need to apply multiple daily doses or use slow-release formulation approaches to maintain effective concentrations at target tissues over extended experimental periods. The Cu²⁺-complexed form shows modestly extended stability relative to the free peptide, likely because the metal coordination partially protects the Gly-His amide bond from endopeptidase access. ^[3]

For in-vitro cell culture experiments, the primary pharmacokinetic concern is stability of the stock solution between preparation and use. Reconstituted GHK-Cu in PBS at 4 °C retains >95% purity for up to 7 days by HPLC measurement. Researchers planning longer-duration experiments should prepare working aliquots for each experimental time point and store unused aliquots at -80 °C in single-use volumes to avoid repeated freeze-thaw degradation.

Purity and Verification

Reading the Certificate of Analysis

The CoA for GHK-Cu has several peptide-specific features that differ from standard small-molecule CoAs. Purity by reverse-phase HPLC (typically a C18 column, acetonitrile/water mobile phase with TFA modifier, UV detection at 220 nm) should show a dominant single peak with ≥98% area. The blue-violet colour indicates that copper chelation is present; a pale or white powder suggests either missing copper or significant degradation, and a CoA showing peptide purity without copper confirmation is insufficient for mechanism studies dependent on the Cu²⁺ component.

Mass spectrometry confirmation is the gold standard for identity. The expected monoisotopic [M+H]⁺ for GHK-Cu complex is approximately 403.1 Da, and the characteristic copper isotope pattern (⁶³Cu/⁶⁵Cu at 69/31 natural abundance) should be visible in the MS spectrum as a doublet with the expected +2 Da satellite. Absence of the copper isotope pattern, or a dominant ion at m/z 341.1 (the free peptide [M+H]⁺), indicates loss of copper chelation. Researchers should request raw MS data rather than a text summary.

Residual trifluoroacetic acid (TFA) from SPPS purification is a common contaminant that can affect cell viability at concentrations above approximately 0.1% w/v in culture media. For GHK-Cu at working concentrations of 1-10 µM (approximately 0.4-4 µg/mL), the contribution of TFA from a 0.1% residual in the powder would be negligible at these dilutions. Researchers should nonetheless confirm residual TFA content for protocols involving higher stock concentrations or sensitive primary cell lines.

Endotoxin testing by limulus amebocyte lysate (LAL) assay is mandatory for cytokine-related endpoints. LPS contamination at even sub-nanogram levels can confound NF-κB, IL-6, and TNF-α measurements entirely. A result below 1 EU/mg is adequate for most in-vitro applications; researchers using macrophage or dendritic cell cultures should apply a more stringent threshold of <0.1 EU/mg.

Independent Verification Strategy

For laboratories receiving a new GHK-Cu batch, independent verification can be conducted with basic analytical equipment. UV-Vis spectroscopy of a 1 mg/mL solution in water should show an absorption maximum between 560-580 nm (the d-d transition of the Cu²⁺ square-planar complex); absence of this peak confirms missing copper. A simple copper colorimetric assay (e.g., bicinchoninic acid copper assay or bathocuproine assay) can semi-quantitatively confirm copper stoichiometry. HPLC verification using in-house instrumentation, if available, provides the most definitive purity confirmation and is recommended for any GHK-Cu batch entering a publication-quality experiment.

Collaboration with an analytical core facility for MS confirmation is recommended before the first use of a new vendor batch, particularly if the experiment involves downstream transcriptomic or proteomic readouts where compound identity uncertainty would compromise data interpretation. For guidance on reading peptide CoAs and selecting suppliers based on documentation quality, see our dedicated resource at /suppliers.

Dosage and Reconstitution

Reconstitution Protocol

GHK-Cu 50 mg lyophilised powder reconstitutes readily in sterile water or phosphate-buffered saline (PBS, pH 7.4). Unlike many research peptides, GHK-Cu does not require acetic acid or DMSO co-solvent. Dissolve directly in sterile water at room temperature; gentle vortexing or pipette mixing is sufficient. A blue-violet colour should develop within seconds, confirming copper chelation.

For detailed step-by-step reconstitution technique including sterile filtration, aliquot preparation, and equipment requirements, see the site guide at /guides/how-to-reconstitute-peptides.

Worked Example 1, 1 mM Stock Solution: To prepare a 1 mM stock from 50 mg GHK-Cu (MW 402.9 Da as complex):

• Number of mmol in 50 mg = 50 / 402.9 = 0.1241 mmol = 0.1241 mM in 1 mL, or 1 mM in 0.1241 mL
• For practical purposes: dissolve 50 mg in 0.124 mL (124 µL) sterile water to obtain approximately 1 mM stock.
• More workably: dissolve 50 mg in 5 mL sterile water to obtain a 24.8 mM stock, then dilute 1:24.8 for 1 mM.
• Or dissolve 50 mg in 10 mL for a 12.4 mM intermediate stock. Aliquot and store at -80 °C.

Worked Example 2, In-Vitro Working Concentration (1 µM):

• Starting from a 1 mM stock (1,000 µM), prepare 1 µM working solution by diluting 1:1,000.
• For a 96-well plate (0.2 mL per well, 80 wells): total volume needed = 16 mL working solution.
• Add 16 µL of 1 mM stock to 15,984 µL culture medium. Mix gently before aliquoting to wells.
• Volume of 50 mg vial stock consumed per 96-well plate experiment: 16 µL of 1 mM stock = 16 µg GHK-Cu.
• One 50 mg vial therefore supports approximately 3,125 such 96-well plate experiments at 1 µM working concentration.

Worked Example 3, Ex-Vivo Skin Permeation Study:

• Literature protocols for Franz diffusion cell studies typically apply GHK-Cu at 0.5-2% w/v in the donor phase.
• At 2% w/v: 2 g per 100 mL = 20 mg/mL. For 10 donor chambers at 1 mL each: 200 mg GHK-Cu required.
• This exceeds a single 50 mg vial; researchers planning topical permeation studies should order 4-5 vials per experimental run.
• Prepare donor-phase solution fresh the day of the experiment; do not store dissolved at room temperature for more than 4 hours at these high concentrations due to oxidation risk.

For assistance with calculating volumes, concentrations, and molar equivalents for other experimental formats, see /guides/how-to-calculate-dosage.

Literature-Reported Research Doses

The following table summarises concentration ranges used in peer-reviewed studies for different experimental systems. These are presented strictly as reported literature values to guide research protocol design.

Side Effects and Safety

In-Vitro and Animal Safety Profile

Within the peer-reviewed literature, GHK-Cu demonstrates a favourable in-vitro cytotoxicity profile at concentrations used for mechanistic experiments. Cell viability assays (MTT, LDH) in human fibroblast, keratinocyte, and dermal papilla cell lines show no significant cytotoxicity at concentrations up to 10 µM, with mild concentration-dependent reductions in viability observed only above 100 µM in most studies. ^[8] The therapeutic window between the bioactive concentration range (0.01-10 µM) and the cytotoxic range (>100 µM) is therefore at least one to two orders of magnitude in standard cell culture models.

In rodent in-vivo studies, GHK-Cu administered subcutaneously at research doses up to 5 mg/kg in rats and mice has not produced acute toxicity signs in the published literature, and histopathological examination of liver and kidney tissues at these doses has not shown organ-level pathology. ^[3] Chronic dosing studies extending beyond 4 weeks are sparse in the literature, representing a genuine knowledge gap. Researchers designing longer-duration animal model experiments should include comprehensive toxicology panels as part of the experimental design and obtain appropriate ethical approval.

Copper-Specific Safety Considerations

Copper toxicity is a legitimate concern when working with any copper-containing compound. At the concentrations used in typical in-vitro GHK-Cu experiments, the molar copper contribution is in the nanomolar to low-micromolar range, well below the concentrations associated with copper-mediated cytotoxicity (which typically requires free Cu²⁺ in the millimolar range). The chelated form of copper in GHK-Cu has substantially reduced direct reactivity compared to free copper ions, which lowers both catalytic oxidative toxicity and cellular copper overload risk. ^[5]

For ex-vivo skin model experiments, the copper content of topically applied GHK-Cu formulations should be considered when interpreting results in the context of copper-accumulating skin conditions or in skin from donors with Wilson's disease or Menkes disease phenotypes. These are specialised research scenarios; standard healthy-donor skin explants are not expected to show copper toxicity at doses consistent with cosmetic research protocols.

Handling and Biosafety

GHK-Cu is not classified as a controlled substance and does not appear on Schedule I or II lists in the United States, the EU, or the UK. Standard laboratory PPE applies: gloves (nitrile), safety glasses, and lab coat for handling. The blue colouration of concentrated solutions can stain skin and clothing; disposable gloves are recommended when handling concentrated stocks. Aerosol generation should be avoided during powder handling; a ventilated weighing hood is appropriate. No specific biohazard designation applies to this compound in its lyophilised or reconstituted form.

Waste disposal should follow institutional guidelines for peptide research reagents. GHK-Cu in aqueous solution is biodegradable; inactivation before drain disposal is not required under standard laboratory regulations in most jurisdictions, though researchers should confirm local rules.

How It Compares

GHK-Cu occupies a specific niche among research peptides and copper-binding compounds. The following comparison positions it against the most commonly used alternatives in cosmetic-science and tissue-repair research programmes.

GHK-Cu vs. Palmitoyl Tripeptide-1

Palmitoyl tripeptide-1 (Pal-GHK) is the lipophilised derivative of GHK, in which palmitic acid is conjugated to the N-terminal glycine. The palmitoyl group substantially increases lipophilicity (log P shifts from approximately -2.5 for GHK to +3.5 for Pal-GHK), enhancing incorporation into lipid-based formulations and transdermal delivery vehicles. ^[15] However, the palmitoyl modification eliminates the N-terminal free amine, which is one of the four copper-coordinating groups in GHK-Cu, meaning Pal-GHK cannot form the same square-planar Cu²⁺ complex. Researchers should therefore not treat Pal-GHK as a copper-delivering equivalent of GHK-Cu; the two compounds have overlapping but distinct mechanism profiles.

For researchers studying matrix synthesis endpoints in cell culture (where copper delivery is not the primary research question), Pal-GHK may provide a useful comparison point. For any research question dependent on Cu²⁺-specific mechanisms (cuproenzyme activation, Nrf2/HO-1 induction, or antioxidant phenotypes), GHK-Cu is the appropriate choice and Pal-GHK is not an adequate substitute.

GHK-Cu vs. Palmitoyl Pentapeptide-4 (Matrixyl)

Matrixyl (palmitoyl-KTTKS) has a substantially different sequence and mechanism, operating primarily through TGF-β pathway activation and producing upregulation of collagen I, III, IV, and fibronectin. ^[15] It lacks copper-binding capacity entirely. Where GHK-Cu's evidence base is stronger for inflammatory modulation and cuproenzyme-linked matrix remodelling, Matrixyl's evidence base is stronger for pure collagen-synthesis induction in 3D culture models and has a modest body of human clinical data from cosmetic product studies (though these share the same limitations of proprietary formulation confounding noted for GHK-Cu clinical studies).

For a researcher interested in comparing matrix synthesis pathways, using both GHK-Cu and Matrixyl in parallel experiments with appropriate controls represents a well-designed comparative approach. The two compounds activate partially overlapping but distinguishable downstream pathways, making direct comparison informative for mechanism delineation.

Where to Buy

Apollo Peptide Sciences supplies the GHK-Cu 50 mg vial reviewed here at $65.00 ($1.30/mg). See our full vendor review at /product/ghk-cu, which includes batch-specific CoA documentation, shipping and handling conditions, and independent verification notes. Our broader supplier evaluation framework, including criteria for CoA quality, independent testing, and cold-chain logistics, is detailed at /suppliers.

When comparing vendor options, prioritise: HPLC purity ≥98% confirmed by chromatogram (not text statement alone); ESI-MS with visible copper isotope pattern; LAL endotoxin testing; and cold-chain shipping with ice pack or dry ice for summer shipments. The 50 mg vial format from Apollo is well-suited for the breadth of research applications covered in this review, and the price point is competitive relative to comparable specifications from other catalogued vendors reviewed on this site.

Open Research Questions

Several important mechanistic and translational questions remain unresolved in the GHK-Cu literature and represent productive directions for original research programmes.

The receptor identification problem. Despite five decades of study, no single high-affinity receptor for GHK-Cu has been identified and validated by crystallography or rigorous pharmacological profiling. The integrin-FAK activation model is supported by correlative data but direct binding affinity measurements are absent. A systematic cryo-EM or surface plasmon resonance study of GHK-Cu interactions with integrin ectodomains would substantially advance mechanistic understanding. ^[6]

Copper stoichiometry in biological effects. It remains unclear what proportion of GHK-Cu's biological effects are attributable to the peptide sequence and what proportion are attributable to copper delivery. Studies using GHK (copper-free) as a comparator alongside GHK-Cu and equimolar CuSO₄ in the same cellular assay would allow partial dissection of these contributions, but few studies have applied this three-arm design rigorously. ^[5]

The 4,000-gene claim. The Pickart-Margolina transcriptomic analysis requires validation by direct RNA-sequencing of GHK-Cu-treated versus vehicle-treated human cell lines under controlled conditions. A purpose-designed whole-transcriptome study with multiple concentration time points would either validate or constrain the scope of the bioinformatic prediction. ^[7]

Hair follicle organ culture validation. The Kang DPC study provides compelling cell-level data, but translation to whole hair follicle organ culture (the most relevant preclinical model) has not been published in the peer-reviewed literature as of the time of this review. This is a tractable experimental gap that could be addressed with commercially available hair follicle organ culture kits. ^[14]

Chronic in-vivo safety data. Published rodent in-vivo studies extend to approximately 4 weeks of dosing. Longer-term safety and pharmacodynamic data from systematic animal studies would strengthen the research foundation for any future investigational application.

FAQ